Patent application number | Description | Published |
20090082336 | mGluR1 Antagonists as Therapeutic Agents - In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J | 03-26-2009 |
20090105248 | 3-MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS - Compounds of the formula | 04-23-2009 |
20090192178 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS - In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J | 07-30-2009 |
20110065738 | POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF - The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease. | 03-17-2011 |
20120028975 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF - The present invention relates to substituted triazolopyridines and analogs thereof, the use of the compounds as phosphodiesterase 10 (PDE10) inhibitors for the treatment of PDE10-modulated disorders, to pharmaceutical compositions comprising the compounds. | 02-02-2012 |
20120316176 | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF - The present invention relates to derivatives of 7,8-dihydro-1H-imidazo[2,1-b]purin-4(5H)-one, compositions thereof and methods of use thereof for treating or preventing pain or an inflammatory disease. | 12-13-2012 |
20140194404 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES - This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation. | 07-10-2014 |
20150299224 | INHIBITORS OF IRAK4 ACTIVITY - The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases. | 10-22-2015 |